To investigate the effect of denogestrin and ethinylestradiol cycloproterone in the treatment of endometriosis(EMs)and the differential expression of serum soluble interleukin-2 receptor(sIL-2R).

This study was a prospective cohort study, a total of 75 female patients with EMs were selected in the obstetrics and gynaecology department of the Xiangyang Central Hospital Affiliated Hospital of Hubei University of Arts and Sciences from February 2020 to December 2021, aged(32.45±5.12)years old, ranging from 22 to 44 years old.The patients were randomly divided into two groups by random number table method: denorgestrel group(n=38)and ethinylestradiol cyprogesterone group(n=37).The denorgestrel group was treated by oral administration of denorgestrel, and the ethinylestradiol cyprogesterone group was treated by oral administration of ethinylestradiol cyprogesterone.The therapeutic effects of the two groups were observed.The changes of visual analogue score(VAS)before and after 6 months of treatment were recorded by VAS, and the serum follicle stimulating hormone(FSH)Serum sIL-2R levels of luteinizing hormone(LH)and estrogen were detected by enzyme-linked immunosorbent assay before and after treatment, and the safety of the two treatment methods was compared.

After 6 months of treatment, the effective rate of ethinyl estradiol cyprogesterone group[97.4%(37/38)]was higher than that of denogestrin group[75.7%(28/37)]; The VAS score[(21.35±4.33)points]in the dinogestrel group was lower than that in the ethinylestradiol cycloproterone group[(45.68±7.12)points]; FSH[(2.74±0.40)U/L], LH[(2.13±0.58)U/L], and estrogen[(62.74±10.40)pmol/L]in the dinogestrel group were lower than those in the ethinylestradiol cycloproterone group[(3.88±0.56)U/L, (3.06±0.82)U/L, and(90.88±15.56)U/L]; The serum sIL-2R[(285.61±22.43)U/L]in ethinylestradiol cycloproprogesterone group was higher than that in denogestrin group[(241.75±16.88)U/L]; The incidence of adverse reactions[21.1%(8/38)]of patients in the dinogestrel group was lower than that of patients in the ethinylestradiol cycloproterone group[46.0%(17/37)], differences were statistically significant(P<0.05).

Compared with ethinylestradiol cycloproterone contraceptives, denogestrin is more effective in the treatment of patients with EMs, and has better pain relief effect.It can effectively improve the hormone level of patients and reduce the expression level of sIL-2R, and has higher safety.

Dinogestrel; Ethinyl estradiol cycloproprogesterone; Endometriosis; Soluble interleukin-2 receptor